drugset
drugset / Trial / NCT04325620

Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease

NCT04325620 ↗

Phase 3 Completed 208 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in patients with Non-erosive gastroesphageal reflux disease.

Timeline

Start
2019-06-10
Primary completion
2020-08-03
Completion
2020-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule — Oral

Indications

gastroesophageal reflux disease